Claudins as diagnostic tools and therapeutic targets-Glimpse of the horizon

  • Cancer Treat Rev. 2025 Feb:133:102888. doi: 10.1016/j.ctrv.2025.102888.
Keiji Sugiyama  1 ,  Ian Chau  2
Affiliations
  • 1. Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London and Surrey, UK; Department of Medical Oncology, NHO Nagoya Medical Center, Nagoya, Aichi, Japan.
  • 2. Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, London and Surrey, UK. Electronic address: [email protected].
PMID: 39847825 DOI: 10.1016/j.ctrv.2025.102888
Abstract

Claudins (CLDNs) play a crucial and indispensable role as fundamental components within the structure of tight junctions. Due to the distinct and unique distribution pattern exhibited by CLDNs in both normal and malignant tissues, these proteins have garnered significant attention as pivotal targets for systemic anti-cancer therapy and as noteworthy diagnostic markers. This review provides a comprehensive and detailed elucidation of the fundamental understanding surrounding CLDNs, their intricate expression patterns, the potential role they play in Cancer diagnosis and therapeutic potentials; all encapsulated within a succinct summary of the cutting-edge advancements and the information derived from various clinical trials.

Keywords
Antibody; Antibody-drug conjugates; Cancer treatment; Claudin; chimeric antigen receptor T cells.